NanosVet Raises $8.3M Seed to Scale Nanotech Pet Drug Delivery

NanosVet Secures $8.3M Seed Round

NanosVet, which does business as Nanos, has raised an $8.3 million seed round. The Los Angeles-based pet-health company is applying nanotechnology to animal drug delivery, and the new capital lands as it continues to build out a direct-to-consumer model for pet parents.

What the Company Does

Nanos is focused on transforming how medications are delivered to animals. Its proprietary NanoMelt strips are pharmaceutical-grade formulations engineered to dissolve in under 30 seconds. According to the company, the format is designed for faster absorption than conventional delivery methods, replacing pills and needles.

The product line spans several common pet-care categories:

• Dental care
• Calming
• Joint support
• Skin support

The company sells directly to pet parents online, pairing its delivery format with veterinary expertise and personalized dosing. That combination positions Nanos at the intersection of pet health, formulation science, and consumer e-commerce.

Funding Details

• Round type: Seed
• Amount raised: $8,300,000
• Currency: USD
• Funding date: September 18, 2026
• Funding stage (company): Seed

No lead investor was disclosed in the funding data, and no additional investors were listed.

Why the Delivery Format Matters

The pitch behind Nanos rests on a simple friction point in pet care: getting animals to take medication. Pills can be difficult to administer, and needles require veterinary visits or at-home injections that many owners are not comfortable performing. A strip that dissolves in under 30 seconds addresses both problems at once, and the company's emphasis on faster absorption suggests a formulation advantage rather than a purely convenience-driven product.

Because the strips are described as pharmaceutical-grade, the company is positioning itself closer to the regulated end of the pet-health spectrum than a typical consumer pet supplement brand. That distinction matters for how the business scales, how it is regulated, and how it is valued by strategic acquirers.

Distribution and Go-to-Market

Nanos sells direct to pet parents online. The direct-to-consumer channel gives the company control over pricing, customer relationships, and data on how pet owners use its products. It also allows Nanos to pair its delivery format with veterinary expertise and personalized dosing, which can function as both a trust signal and a retention mechanism.

For acquirers in pet health, veterinary pharmaceuticals, or consumer pet brands, a DTC channel with personalized dosing is an asset: it produces first-party data and recurring purchase behavior that can be layered onto existing retail or clinic distribution.

What the Seed Round Signals

An $8.3 million seed round is a meaningful raise for a pet-health company at this stage. It suggests investors see room for a differentiated delivery platform rather than a single product. The categories Nanos is targeting — dental, calming, joint, and skin — are among the highest-frequency concerns in pet care, which gives the company multiple paths to repeat revenue from the same customer base.

The absence of a disclosed lead investor means the round structure is not fully visible from the available data. What is clear is the amount, the stage, and the timing.

Acquisition Angle

Nanos sits at a crossroads that tends to attract strategic interest:

• Formulation IP: Proprietary NanoMelt strips represent defensible technology rather than a white-label product.
• Delivery innovation: Replacing pills and needles is a durable problem statement with clear consumer demand.
• DTC infrastructure: An online channel with personalized dosing creates customer data and repeat-purchase economics.
• Category breadth: Dental, calming, joint, and skin support give the platform multiple expansion vectors.

For larger pet-health, animal pharmaceutical, or consumer packaged goods players, Nanos offers a technology layer that could be applied across an existing product portfolio, plus a direct relationship with pet parents that is difficult to replicate quickly.

The Bottom Line

NanosVet has raised $8.3 million in seed funding to advance nanotechnology-based drug delivery for pets. With NanoMelt strips that dissolve in under 30 seconds, a DTC sales model, and a product roadmap spanning dental, calming, joint, and skin support, the company is building a platform play in a category where delivery — not just formulation — has long been the bottleneck.